ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0561

Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry

Lucia Margarita Mendoza Martinez1, Joan Manuel Dapeña1, Juan Manuel Bande1, Maria Alejandra Medina1, Silvia Papasidero1, José caracciolo1, Rosana Quintana2, Lucila Garcia2, Carla Andrea Gobbi2, Sandy Sapag Durán2, Alberto Spindler2, Analia Patricia Alvarez2, Cecilia Pisoni2, Catalina Gomez2, Raúl Hector Paniego2, María Julia Santa cruz2, Luciana Gonzalez Lucero2, Rodrigo Aguila Maldonado2, Sergio Gordon2, Julia Romero2, Gretel Rausch2, Alberto Allievi2, Alberto Omar Orden2, johana zacariaz hereter3, Roberto Baéz2, Andrea Vanesa González2, Juan Manuel Vandale2, Mario Alberto Goñi2, Victor Caputo4, María Silvia Larroudé2, Graciela Gómez2, Josefina Marin2, Victoria Collado2, Gazzoni María Victoria2, Marcos David Zelaya2, Mónica Sacnún2, Romina Rojas Tessel2, Maira Alejandra Arias Saavedra2, Maximiliano Machado Escobar2, Pablo Astesana2, Ursula Vanesa Paris2, Bernando A. Pons-Estel2 and Mercedes García5, 1Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 2Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Hospital Militar Central, Buenos Aires, Argentina, 5Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), Cohort Study, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-Ro antibodies can be detected in 40% of patients with systemic lupus erythematosus (SLE) and have been associated with various clinical manifestations of the disease as well as maternal-fetal complications. The aim of this study was to describe the frequency of anti-Ro antibodies in SLE patients and to assess their association with disease characteristics, maternal-fetal complications, treatment, morbidity and mortality.

Methods: Retrospective observational study. Data from SLE patients of the National Registry of the Argentine Society of Rheumatology (RELESSAR) were used. Sociodemographic data, comorbidities, disease characteristics, maternal-fetal complications, SLE morbidity and mortality, activity and damage scores were recorded.

Statistical analysis: Descriptive statistics. Appropriate tests (Chi2, Fisher, Student’s t-test or Wilcoxon), and univariate/multivariate logistic regression analyses were conducted to identify factors associated with presence of anti-Ro antibodies.

Results: A total of 1513 patients were included. Patient characteristics are shown in Table 1. Anti-Ro antibodies were requested in 88% (n=1331), of which 41% (n=552) were positive. Characteristics of patients with positive and negative Anti-Ro antibodies can be observed inTable 2. Anti-Ro antibodies were associated with hypocomplementemia (p< 0.05), anti-La antibodies (< 0.001), anti-Sm antibodies (p< 0.001), anti-RNP antibodies (p< 0.001) and Sjogren’s syndrome (p< 0.001). Also were associated with Raynaud’s phenomenon (p< 0.004), pericarditis (p< 0.005) and interstitial pneumonitis (p< 0.02). More infections (p< 0.01) and a greater use of corticosteroids (p< 0.04) and methotrexate (p< 0.04) were observed. Univariate analysis in patients with Anti-Ro determination is shown in table 3. In the multivariate model, the independent variables were anti-Sm antibodies (OR 1.9, 95% CI 1.4-2.5), anti-La antibodies (OR 48, 95%CI 26-99), chronic thyroiditis (OR 1.9, 95%CI 1.3-2.7) and the use of methotrexate (OR 0.66, 95%CI 0.5-0.9).

Conclusion: In this SLE patients, anti-Ro positivity was associated with the presence of other antibodies, chronic thyroiditis and methotrexate use, but not with any specific clinical profile, maternal-fetal complications or SLE-related morbidity and mortality.

Supporting image 1

Table 1. Patient characteristics (N=1513)

Supporting image 2

Table 2. Characteristics of patients with positive and negative anti-Ro antibodies

Supporting image 3

Table 3. Univariate analysis in patients with Anti-Ro determination (N=1331)


Disclosures: L. Mendoza Martinez: None; J. Dapeña: None; J. Bande: None; M. Medina: None; S. Papasidero: None; J. caracciolo: None; R. Quintana: None; L. Garcia: None; C. Gobbi: None; S. Sapag Durán: None; A. Spindler: None; A. Alvarez: None; C. Pisoni: None; C. Gomez: None; R. Paniego: None; M. Santa cruz: None; L. Gonzalez Lucero: None; R. Aguila Maldonado: None; S. Gordon: None; J. Romero: None; G. Rausch: None; A. Allievi: None; A. Orden: None; j. zacariaz hereter: None; R. Baéz: None; A. González: None; J. Vandale: None; M. Goñi: None; V. Caputo: None; M. Larroudé: None; G. Gómez: None; J. Marin: None; V. Collado: None; G. María Victoria: None; M. Zelaya: None; M. Sacnún: None; R. Rojas Tessel: None; M. Arias Saavedra: None; M. Machado Escobar: None; P. Astesana: None; U. Paris: None; B. Pons-Estel: None; M. García: GSK, 6, Janssen, 6, Pfizer, 6.

To cite this abstract in AMA style:

Mendoza Martinez L, Dapeña J, Bande J, Medina M, Papasidero S, caracciolo J, Quintana R, Garcia L, Gobbi C, Sapag Durán S, Spindler A, Alvarez A, Pisoni C, Gomez C, Paniego R, Santa cruz M, Gonzalez Lucero L, Aguila Maldonado R, Gordon S, Romero J, Rausch G, Allievi A, Orden A, zacariaz hereter j, Baéz R, González A, Vandale J, Goñi M, Caputo V, Larroudé M, Gómez G, Marin J, Collado V, María Victoria G, Zelaya M, Sacnún M, Rojas Tessel R, Arias Saavedra M, Machado Escobar M, Astesana P, Paris U, Pons-Estel B, García M. Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/frequency-of-anti-ro-antibodies-in-systemic-lupus-erythematosus-patients-insights-from-multicenter-and-national-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-of-anti-ro-antibodies-in-systemic-lupus-erythematosus-patients-insights-from-multicenter-and-national-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology